Get the Stockscreener App
28.67
2.32%
0.65
After Hours:
28.67
Cg Oncology Inc stock is traded at $28.67, with a volume of 1.19M.
It is up +2.32% in the last 24 hours and down -11.07% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$28.02
Open:
$27.58
24h Volume:
1.19M
Relative Volume:
1.70
Market Cap:
$2.18B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-69.06M
1W Performance:
-0.31%
1M Performance:
-11.07%
6M Performance:
-10.71%
1Y Performance:
+0.00%
1-Day Range:
$27.58
$28.94
1-Week Range:
$27.00
$30.00
52-Week Range:
$25.77
$50.23
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
28.67 | 2.18B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 2,503 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology (NASDAQ:CGON) Shares Down 4.3%Time to Sell? - MarketBeat
CG Oncology Enters Oversold Territory (CGON) - Nasdaq
State Street Corp Raises Stake in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
State Street Corp Acquires 717,722 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Cg oncology director Leonard Post sells $28,840 in stock By Investing.com - Investing.com Australia
Franklin Resources Inc. Has $46.16 Million Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Cg oncology director Song Hong Fang sells shares worth $19.6 million - Investing.com India
Hong Fang Song Sells 700,000 Shares of CG Oncology, Inc. (NASDAQ:CGON) Stock - MarketBeat
Cg oncology director Leonard Post sells $28,840 in stock - Investing.com
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares - Marketscreener.com
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Marketscreener.com
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - The Manila Times
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase - EIN News
CG Oncology's SWOT analysis: cretostimogene's potential reshapes NMIBC stock outlook - Investing.com
CG Oncology's SWOT analysis: cretostimogene's potential reshapes NMIBC stock outlook By Investing.com - Investing.com South Africa
Jane Street Group LLC Buys 138,400 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Latham & Watkins Advises on CG Oncology’s Public Offering - Legal Desire News Network
CG Oncology (NASDAQ:CGON) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Wellington Management Group LLP Acquires 308,852 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
CG Oncology (NASDAQ:CGON) vs. LENZ Therapeutics (NASDAQ:LENZ) Head-To-Head Survey - Defense World
CG Oncology (NASDAQ:CGON) versus Fresh Tracks Therapeutics (NASDAQ:FRTX) Head-To-Head Comparison - Defense World
Cg Oncology Inc (NASDAQ: CGON) Has Great Upside Potential - Stocks Register
CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene (NASDAQ:CGON) - Seeking Alpha
Fmr LLC Raises Stock Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
CG Oncology Launches Major $204M IPO with Shares Priced at $28, Backed by Top Wall Street Banks - StockTitan
CG Oncology Announces Pricing of Public Offering - Marketscreener.com
CG Oncology Announces Pricing of Public Offering - GlobeNewswire Inc.
CG Oncology announces 7.3M share offering - MSN
Neo Ivy Capital Management Takes Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Why CG Oncology (CGON) Stock Is Down 9% - Benzinga
CGONCG Oncology, Inc. Latest Stock News & Market Updates - StockTitan
CG Oncology announces offering of 8M shares of common stock - TipRanks
CG Oncology Announces Proposed Public Offering - The Manila Times
Costco Wholesale (COST-Q) QuotePress Release - The Globe and Mail
CG Oncology Launches Major 8M Share Public Offering, Backed by Top Wall Street Banks - StockTitan
CG Oncology files to sell 8M shares of common stock - TipRanks
CG Oncology, Inc. (NASDAQ:CGON) Position Boosted by BNP Paribas Financial Markets - MarketBeat
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer Research Fellowship Award - Marketscreener.com
CG Oncology’s (CGON) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Charles Schwab Investment Management Inc. Purchases 202,262 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post Sells 1,000 Shares - MarketBeat
Royal Bank of Canada Reaffirms Outperform Rating for CG Oncology (NASDAQ:CGON) - MarketBeat
HC Wainwright Reaffirms Buy Rating for CG Oncology (NASDAQ:CGON) - MarketBeat
Cg oncology director Leonard Post sells shares worth $34,541 By Investing.com - Investing.com Nigeria
Cg oncology director Leonard Post sells shares worth $34,541 - Investing.com
Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer - Reuters.com
CG Oncology keeps stock target with buy rating, impresses with Phase 3 results - Investing.com
Cg Oncology Inc’s (CGON) -6.54% Drop Is A Reason To Reconsider. - Stocks Register
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
CG Oncology Launches Groundbreaking Research Fellowship for Bladder Cancer Innovation - StockTitan
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):